TILT Biotherapeutics, a biotech company developing cancer immunotherapies, has announced that the first patient has been dosed in a phase 1 trial of the company’s oncolytic adenovirus TILT-123.
The South Korean company is set to create a new facility in West Virginia to house insulin manufacturing and to deliver its insulin products in the country.
Breath biopsy specialist, Owlstone Medical, has entered into a research agreement with biotech company, Bicycle Therapeutics plc, to access its bicyclic peptide technology.
The US biotech CytomX has lost a collaboration partner as AbbVie pulled out of a collaboration developing an antibody-drug conjugate (ADC) for the treatment of solid tumours.
Switzerland headquartered Lonza said it is expanding its early development services (EDS) to North America, opening a new laboratory in Cambridge, Massachusetts (US).
Amgen joins the Winn Award Program that was set up by Bristol Myers Squibb, with plans to extend the reach of clinical trials into underserved patient populations in the US.
Pyxis Oncology has received clearance for two IND applications from the US Food and Drug Administration (FDA) to initiate two Phase 1 clinical studies.
BioNTech is set to take several mRNA candidates into clinical trials over the coming months: including vaccines for shingles, malaria and tuberculosis.
Acumen Pharmaceuticals believes ACU193 – the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβO) – offers the promise of an effective treatment with a better safety profile than other Alzheimer's...
The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.
The US Food and Drug Administration (FDA) has awarded 19 new grants and two new contracts totaling more than US$38m in funding over the next four years to support clinical trials and natural history studies related to rare diseases.
The Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period, found research by GlobalData.
The research institutions are joining on a community-based collaborative initiative to work toward greater study inclusion, supported by funding from PhRMA.
The pharmaceutical company is expanding its alliance with historically Black medical schools to bolster the battle against systemic health disparities.
What are the opportunities, challenges and innovation drivers across healthcare? From its 2022 Global Annual Meeting, the DIA tells us the key issues it's keeping its eyes on.
Unveiled at the 2022 BIO International Convention, the group's third annual diversity, equity, and inclusion report spotlights improvements both made and needed.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation to improve and strengthen UK clinical trials legislation.
Regulatory bodies in the European Union have launched an initiative to develop the region as a focal point for clinical research and to better integrate clinical research in the European health system.
The World Health Organization’s Solidarity PLUS trial will kick off in 52 countries, trialing three drugs to treat patients hospitalized with COVID-19.
These organizations hope to connect with attendees at the event, sharing clinical research ideas and innovations in sessions and the virtual exhibit hall.
The EMPHATHY clinical trial will enroll patients with COVID-19 to test the drug’s effectiveness in preventing worsening of symptoms and hospitalization.
More than 360,000 people have signed up to the UK’s registry of people interested in participating in vaccine trials: the world’s first database of its kind. The UK is also exploring other measures – such as human challenge trials - to boost clinical...
The clear evidence of increased risk of COVID-19 infection amongst ethnic minority groups, people from Black and Asian backgrounds, is of urgent public health importance, according to the authors of a paper published today by The Lancet.
AstraZeneca paused its COVID-19 vaccine trial earlier this month for a safety review – generating headlines across mainstream press worldwide. Such pauses are not uncommon in clinical trials – so what’s the best way to deal with them?
The chief executives of nine leading biopharma companies have moved to reassure the public over the development and testing procedures for Covid-19 vaccines.
While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.
Johnson & Johnson has unveiled a vaccine facility in Leiden, the Netherlands, which will focus on R&D, technological development, and large-scale production of vaccines for late-stage clinical trials.
Cryoport is supporting a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry, says CCO.
Drug firms that want to trial or sell vaccines in India, or import them into the country, will need to seek CDSCO permission via an online portal from now on.
A professor who conducted fast-track trials during last year’s Ebola outbreak says next time such trials must be part of humanitarian response… because there will be a next time.
Results from all UK-funded vaccine trials will be made public according to Prime Minister David Cameron, who suggested failure to share data exacerbated the Ebola outbreak.
A potential new law mandating the running of clinical trials before
a "generic" biologic drug approval may seem like a potential
goldmine for contract research organisations (CROs), however, this
vision is premature.
